(888) 352-RUSH for help arranging an appointment.
Faculty Rank: Professor
Medical or Graduate Education:
Medical College of Pennsylvania
Rush University Medical Center - Hematology
Rush University Medical Center - Hematology
Blood disorders, cancerous
Blood disorders, noncancerous
Bone marrow aspiration and biopsy
Cutaneous T-cell lymphoma
Leukemias, acute and chronic
Targeted therapy for hematologic cancer
Translational research and targeted therapies for:
Acute and chronic leukemias
Consultants In Hematology Professional Building 1725 W. Harrison St. Suite 1010 Chicago, IL 60612 Phone: (312) 563-2320 Fax: (312) 563-2480
View Larger Map • Driving Directions
Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.
Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients. Karmali R, Paganessi LA, Frank RR, Jagan S, Larson ML, Venugopal P, Gregory SA, Christopherson KW 2nd. J Leukoc Biol. 2013 2013 Jan 93(1):161-70. doi: 10.1189/jlb.0612301. Epub 2012 Nov 7. Successful Treatment of Hepatosplenic T-Cell Lymphoma With ESHAP Followed by Autologous Stem Cell Transplant. Chalmers AW, Katz DA, Miller IJ, Gregory SA. Clin Adv Hematol Oncol. 2013 2013 Feb 11(2):109-13. No abstract available. Ocular Adnexal MALTomas: Case Series of Patients Treated With Primary Radiation. Russell W, Herskovic A, Gessert D, Cohen JA, Rubenstein JB, Gregory SA. Clin Adv Hematol Oncol. 2013 2013 Apr 11(4):209-14. CD26 protease inhibition improves functional response of unfractionated cord blood, bone marrow, and mobilized peripheral blood cells to CXCL12/SDF-1. Christopherson KW 2nd, Frank RR, Jagan S, Paganessi LA, Gregory SA, Fung HC. Exp Hematol. 2012 2012 Nov 40(11):945-52. doi: 10.1016/j.exphem.2012.07.009. Epub 2012 Jul 27. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Evens AM, Helenowski I, Ramsdale E, Nabhan C, Karmali R, Hanson B, Parsons B, Smith S, Larsen A, McKoy JM, Jovanovic B, Gregory S, Gordon LI, Smith SM. Blood. 2012 2012 Jan 19 119(3):692-5. doi: 10.1182/blood-2011-09-378414. Epub 2011 Nov 23. Analysis of very elderly non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome. Nabhan C, Smith SM, Helenowski I, Ramsdale E, Parsons B, Karmali R, Feliciano J, Hanson B, Smith S, McKoy J, Larsen A, Hantel A, Gregory S, Evens AM. Br J Haematol. 2012 2012 Jan 156(2):196-204. doi: 10.1111/j.1365-2141.2011.08934.x. Epub 2011 Nov 16. Relapsed diffuse large B-cell lymphoma--10 years later. Jain S, Shah N, Gregory S. Clin Adv Hematol Oncol. 2011 2011 Sep 9(9):704-8. No abstract available. Clinical and laboratory features of myelofibrosis and limitations of current therapies. Gregory SA, Mesa RA, Hoffman R, Shammo JM. Clin Adv Hematol Oncol. 2011 2011 Sep 9(9 Suppl 22):1-16. Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma. Karmali R, Larson ML, Wooldridge JE, Gregory SA, O'Brien T, Shammo JM, Bueschel K, Venugopal P. Leuk Lymphoma. 2011 Jun 24 Safety and Efficacy of Combination Therapy with Fludarabine, Mitoxantrone, and Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan and Maintenance Rituximab as Front-Line Therapy for Patients With Follicular or Marginal Zone Lymphoma. Karmali R, Kassar M, Venugopal P, Shammo JM, Fung HC, Bayer R, O'Brien T, Gregory SA. Clin Lymphoma Myeloma Leuk. 2011 Jun 22 Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report. Witzig TE, Fishkin P, Gordon LI, Gregory SA, Jacobs S, Macklis R, McLaughlin P, Press O, Zelenetz AD. Leuk Lymphoma. 2011 Jul 52(7):1188-99 In vivo expansion of the megakaryocyte progenitor cell population in adult CD26-deficient mice Kidd S, Bueso-Ramos C, Jagan S, Paganessi LA, Boggio LN, Fung HC, Gregory SA, Christopherson KW 2nd Exp Hematol 2011 Feb 1 Multiple myeloma with multiple extramedullary plasmacytomas. Nangia JR, Lakhani AA, Loew JM, Gregory SA. Clin Adv Hematol Oncol. 2011 2011 Aug 9(8):630-2. No abstract available. Bendamustine's emerging role in the management of lymphoid malignancies. Rummel MJ, Gregory SA. Semin Hematol. 2011 Apr 48 Suppl 1:S24-36 Intravascular B-cell Lymphoma Following Nodal Diffuse Large B-cell Lymphoma Katz DA, Miller IJ, Gregory SA Clin Adv Hematol Oncol 2010 Sep 8(9):637-42 The future of CD20 monoclonal antibody therapy in B-cell malignancies Czuczman MS, Gregory SA Leuk Lymphoma 2010 Jun 51(6):983-94 Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era Evens AM, David KA, Helenowski I, Nelson B, Kaufman D, Kircher SM, Gimelfarb A, Hattersley E, Mauro LA, Jovanovic B, Chadburn A, Stiff P, Winter JN, Mehta J, Van Besien K, Gregory S, Gordon LI, Shammo JM, Smith SE, Smith SM J Clin Oncol 2010 Feb 20 28(6):1038-46 Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA Blood 2010 Apr 1 115(13):2578-85 Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma de Vos S, Goy A, Dakhil SR, Saleh MN, McLaughlin P, Belt R, Flowers CR, Knapp M, Hart L, Patel-Donnelly D, Glenn M, Gregory SA, Holladay C, Zhang T, Boral AL J Clin Oncol 2009 Oct 20 27(30):5023-30 Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia Treon SP, Branagan AR, Ioakimidis L, Soumerai JD, Patterson CJ, Turnbull B, Wasi P, Emmanouilides C, Frankel SR, Lister A, Morel P, Matous J, Gregory SA, Kimby E Blood 2009 Apr 16 113(16):3673-8 Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma Gregory SA, Hohloch K, Gisselbrecht C, Tobinai K, Dreyling M Oncologist 2009 14 Suppl 2:4-16 New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. Summary Bischof Delaloye A, Conti PS, Gisselbrecht C, Gregory SA Oncologist 2009 14 Suppl 2:52-4 New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. Introduction Bischof Delaloye A, Conti PS, Gisselbrecht C, Gregory SA Oncologist 2009 14 Suppl 2:1-3 NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G Maki G, Hayes GM, Naji A, Tyler T, Carosella ED, Rouas-Freiss N, Gregory SA Leukemia 2008 May 22(5):998-1006 Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma Leonard JP, Gregory SA, Maloney DG, Vose JM, Younes A, Zelenetz AD Clin Adv Hematol Oncol 2008 Jun 6(6):437-45 Mesenchymal stem cells from the Wharton's jelly of umbilical cord segments provide stromal support for the maintenance of cord blood hematopoietic stem cells during long-term ex vivo culture Bakhshi T, Zabriskie RC, Bodie S, Kidd S, Ramin S, Paganessi LA, Gregory SA, Fung HC, Christopherson KW 2nd Transfusion 2008 Dec 48(12):2638-44 Idiopathic hemophagocytic syndrome with a fulminant clinical course Khandelwal A, Shah NB, Eichenseer P, Welker M, Miller I, Nangia J, Farhat M, Gimelfarb A, Kassar M, Batus M, Gezer S, Shammo J, Gregory S, Fung H, Venugopal P Clin Adv Hematol Oncol 2008 Aug 6(8):587-90 Localized bone disease as a presentation of hairy cell leukemia Karmali R, Farhat M, Leslie W, McIntire MG, Gregory S Clin Adv Hematol Oncol 2008 Apr 6(4):290-4
To watch a brief video of Stephanie A. Gregory, MD, click the play button at the lower left corner of the video frame below.
(If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
We’re gonna cure one cancer at a time. And it’s gonna be one cancer with a new drug, a new, targeted therapy. We’re going away from many intravenous chemotherapy drugs to pills. There’s one leukemia today that was a hundred percent fatal within three years when I was doing my training many years ago. Today that is cured with a pill that patients take. We now have a 95 percent 10-year survival of those patients. So I’ve seen many, many changes over the years, especially in the area that I work in: the lymphomas, the lukemias, the myelomas. Great progress.
We always say we have the best relationships with our patients because we actually love each other. And the best thing I can ever say to a patient is, “You’re cured.” And that really makes my day.